Technical Analysis for SABS - SAB Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Support | Bullish | -16.22% | |
| Crossed Above 200 DMA | Bullish | -16.22% | |
| Pocket Pivot | Bullish Swing Setup | -16.22% | |
| Wide Bands | Range Expansion | -16.22% | |
| 20 DMA Support | Bullish | -4.91% | |
| Earnings Movers | Other | -4.91% | |
| Outside Day | Range Expansion | -4.91% |
| Alert | Time |
|---|---|
| 200 DMA Resistance | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| 20 DMA Support | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 10% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2024
SAB Biotherapeutics, Inc. Description
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Pharmaceutical Immunology Immune System Immunotherapy Infectious Diseases Diabetes Autoimmune Disease Antibodies Antibody Immunotherapies Influenza Us Government Genetic Engineering Human Diseases Transplantation Glycoproteins Polyclonal Antibodies Type 1 Diabetes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.721 |
| 52 Week Low | 2.16 |
| Average Volume | 85,441 |
| 200-Day Moving Average | 3.56 |
| 50-Day Moving Average | 2.95 |
| 20-Day Moving Average | 3.29 |
| 10-Day Moving Average | 3.56 |
| Average True Range | 0.41 |
| RSI (14) | 48.19 |
| ADX | 26.06 |
| +DI | 21.38 |
| -DI | 15.19 |
| Chandelier Exit (Long, 3 ATRs) | 3.14 |
| Chandelier Exit (Short, 3 ATRs) | 3.83 |
| Upper Bollinger Bands | 4.17 |
| Lower Bollinger Band | 2.41 |
| Percent B (%b) | 0.39 |
| BandWidth | 53.40 |
| MACD Line | 0.15 |
| MACD Signal Line | 0.19 |
| MACD Histogram | -0.0382 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.00 | ||||
| Resistance 3 (R3) | 4.10 | 3.90 | 3.85 | ||
| Resistance 2 (R2) | 3.90 | 3.67 | 3.85 | 3.80 | |
| Resistance 1 (R1) | 3.50 | 3.53 | 3.40 | 3.40 | 3.75 |
| Pivot Point | 3.30 | 3.30 | 3.25 | 3.25 | 3.30 |
| Support 1 (S1) | 2.90 | 3.07 | 2.80 | 2.80 | 2.45 |
| Support 2 (S2) | 2.70 | 2.93 | 2.65 | 2.40 | |
| Support 3 (S3) | 2.30 | 2.70 | 2.35 | ||
| Support 4 (S4) | 2.20 |
